CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology
June 07, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
Pooled analysis of 3 randomized, double-blind, pacebo-cotrolled trials supports the safety and the distinct and favorable tolerability profile of lumateperone 42 mg Mean change from baseline in...
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
May 26, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 10, 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression in adults as both monotherapy and adjunctive treatment with lithium or valproate have been accepted for...
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
May 05, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Host First Quarter 2021 Financial Results Conference Call and Webcast
May 04, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 04, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
May 03, 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting
April 22, 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
Webcast to be Held Tuesday, May 4, 2021 at 2:00 p.m. EDT Webcast Will Feature Key Opinion Leader, Dr. Roger McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto and Head of...
Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting
April 20, 2021 07:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced the nominations of Sir Michael Rawlins and Joel S. Marcus to stand for election to the...
Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annual Meeting
April 12, 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
Our research has demonstrated that the phosphodiesterase type 1 (PDE1) enzyme modulates the immune system by reducing macrophage and microglial activity with demonstrated effects in neuroinflammatory...
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update
February 25, 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
Successfully launched CAPLYTA® (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19. CAPLYTA achieved net product revenues of $12.4 million and...